Why Are Pharmaceutical Companies Racing to Develop Weight Loss Pills?

Hardly a week goes by without someone asking me about a new weight loss medicine. Over the past couple of years, I've watched the conversation around weight loss treatment change faster than at any other point in my career. Several pharmaceutical companies, including Novo Nordisk, Eli Lilly and Pfizer, are investing heavily in new treatments, and the UK now has its first MHRA-approved oral GLP-1 medicine licensed specifically for weight management: the oral Wegovy pill. I want to explain, in plain terms, why this field has become so competitive, what has actually changed here in the UK, and what I think is worth considering if you are weighing up whether treatment might be right for you. This is general information from my professional perspective, not personal medical advice, so please still speak to your own prescriber before making any decisions.

Why Has Weight Loss Become Such a Priority for Pharmaceutical Companies?

From what I see every day, it really comes down to scale. Obesity affects a huge share of the people I see across the counter, and it is closely linked to serious, long-term health conditions. NHS England's Health Survey for England found that 30% of adults were living with obesity in 2024, and 66% were either overweight or living with obesity.

When a condition affects that many people, and a medicine is shown to work safely, it becomes both a genuine public health opportunity and a substantial commercial one. That is really the whole story behind the investment.

One of the biggest changes I've seen is how modern GLP-1 medicines work. Rather than simply trying to suppress appetite, they help regulate it. Many people feel fuller sooner, stay satisfied for longer and find it easier to reduce their calorie intake, which is why these medicines have attracted so much attention.

Why Are Companies Moving From Injections Towards Tablets?

From what I see day to day, tablets are being developed because they are easier to manufacture at scale and because a daily tablet suits people who would never consider a weekly injection. When patients ask me about tablets instead of injections, the same two concerns usually come up.

• Quite a few people are simply put off by needles, even when they might benefit from treatment.
• Injectable pens have faced supply shortages in recent years, so tablets give manufacturers another production route.

One thing I always make clear is that a tablet isn't automatically better than an injection. In my experience, the appeal is mostly about convenience and access, not superior results.

Which Companies Are Leading This Field?

In my professional reading of the market, Novo Nordisk and Eli Lilly are the two biggest players, with several others chasing hard behind them. Novo Nordisk makes semaglutide, sold as Wegovy and Ozempic, while Eli Lilly makes tirzepatide, sold as Mounjaro and Zepbound. Eli Lilly is also developing a separate oral tablet, orforglipron, which is a different molecule to tirzepatide. It has been approved in the United States under the brand name Foundayo, but it has not yet received MHRA approval and is not currently available in the UK.

Pfizer, Amgen and other manufacturers are investing heavily too. This field moves quickly, so I always recommend checking official sources such as GOV.UK or the MHRA for the latest approvals, rather than relying on media headlines alone.

What Has Been Approved for Weight Loss Tablets in the UK?

The Oral Wegovy Tablet (Semaglutide)

As a pharmacist, I was pleased to see the MHRA approve the UK's first oral GLP-1 tablet licensed specifically for weight management in June 2026. It is a real milestone, since earlier oral semaglutide products were only licensed for type 2 diabetes.

Under the official MHRA announcement on GOV.UK, the tablet is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 30 with a weight-related health condition, alongside a reduced-calorie diet and increased physical activity.

The dose is increased gradually under prescriber supervision, and for now the tablet is available privately rather than on the NHS, while a NICE appraisal is awaited.

If you would like to understand the eligibility criteria and consultation process in more detail, our Wegovy pill page explains this clearly.

What Would I Tell a Patient Considering Weight Loss Treatment?

Honestly, I would say it is more choice, not a shortcut. I never recommend starting any prescription weight loss medicine, tablet or injection, without a proper consultation with a registered prescriber who can check if it is safe and suitable for you.

• The first thing I ask about is existing health conditions and current medication, as these can affect whether treatment is suitable.
• We also talk about diet and physical activity, because medication works best alongside healthy lifestyle changes.
• I always explain that results vary, so it's important not to compare your progress with someone else's.

If you want to read more, our weight loss treatment pages cover the wider range of options, including our introduction to GLP-1 medicines and how the Wegovy pill compares with Mounjaro.

How Pharmacy Planet Can Help

If any of this has made you curious about whether a prescription weight loss treatment might be worth exploring, that is exactly the kind of conversation I would want you to have properly, not guess at from an article.

At Pharmacy Planet, we offer an online consultation with a UK-registered prescriber, who will review your medical history and confirm whether a treatment such as the Wegovy pill is suitable and safe for you personally.

You can start an online consultation or read the full eligibility criteria first on our oral Wegovy pill page. Either way, nothing is ever prescribed without that proper assessment first.

This article reflects my professional perspective as a pharmacist and is for general information only. It does not constitute personal medical advice. Prescription-only medicines are available only following a consultation with a registered prescriber, who will confirm whether treatment is appropriate for you.

Frequently Asked Questions

Is the Wegovy pill available on the NHS?

Not at the moment. It is currently available privately, following a consultation with a registered prescriber, while a formal NICE appraisal for NHS use is still awaited. NICE appraisals take time, since they weigh up clinical effectiveness against cost, so I would not expect NHS access in the short term. If you want to check the current position for yourself, NICE publishes its ongoing and completed appraisals on the NICE website, which I would always point patients towards rather than relying on second-hand reports.

How is the Wegovy pill different from the Wegovy injection?

Both contain the same active ingredient, semaglutide, and are licensed for the same purpose, which is weight management alongside diet and exercise. The main practical difference is the route and frequency: the tablet is taken once daily on an empty stomach, while the injection is given once a week regardless of food. It is also worth being clear that this is a different product from Rybelsus, which is a lower-dose oral semaglutide licensed only for type 2 diabetes, not for weight management, so the two should never be confused or substituted for one another.

Who can take the new weight loss tablets?

Under the current UK licence, this is intended for adults with a BMI of 30 or above, or a BMI of 27 to 30 alongside at least one weight-related health condition such as high blood pressure or type 2 diabetes. That said, a BMI figure alone never tells the full story in my consultations. I also need to look at someone's full medical history, current medication and any contraindications before I would consider it appropriate, which is why a proper assessment always has to come before any prescription.

Are oral weight loss medicines safe?

Any medicine I dispense has already been through MHRA review for safety, quality and effectiveness before it reaches a pharmacy, which gives me confidence in recommending it where it is clinically appropriate. That said, "safe" does not mean "without risk" for every individual, since, like all medicines, these tablets can still cause side effects and may not suit everyone. I always tell a patient to follow their prescriber's guidance closely, read the patient information leaflet in full, and report any suspected side effects through the MHRA Yellow Card scheme.

What side effects should I be aware of?

The side effects reported most often with this class of medicine are gastrointestinal, including nausea, diarrhoea, constipation and occasional vomiting, particularly when a dose is first increased. Most people find these settle down over time as the body adjusts, though not everyone tolerates the medicine equally well. I always ask patients to tell me straight away if side effects are severe or persistent, rather than trying to push through them, since the dose or approach may need to be reviewed.

How much weight might I lose, and how quickly?

This is one of the most common questions I hear in practice, and I always give an honest answer rather than a number. Weight loss with any prescription medicine varies considerably from person to person, depending on factors such as starting weight, diet, activity levels and how well the medicine is tolerated. I would rather talk a patient through the clinical evidence properly during a consultation than quote a single figure here that might not reflect their own likely experience.